Methods and compositions for delivering interleukin-1 receptor antagonist
View Patent ↗Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating a liquid volume of white blood cells and platelets with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist.
1. A solution enriched with interleukin-1 receptor antagonist, comprising:
polyacrylamide beads;
white blood cells at a concentration that is greater than the concentration of white blood cells in whole blood; and
interleukin-1 receptor antagonist at a concentration that is at least 10,000 pg/ml.
2. The solution according to claim 1 , wherein the concentration of interleukin-1 receptor antagonist in the solution is at least twice concentration of interleukin-1 receptor antagonist in whole blood.
3. The solution according to claim 1 , wherein the white blood cells are activated by the polyacrylamide beads to release at least a portion of the interleukin-1 receptor antagonist.
4. The solution according to claim 1 , wherein the solution has a concentration of white blood cells that is 28.5±4.8 K/μL.
5. The solution according to claim 1 , further comprising platelets.
6. A solution enriched with interleukin-1 receptor antagonist generated from a white blood cell fraction or a white blood cell concentrate, the solution comprising:
polyacrylamide beads;
white blood cells; and
interleukin-1 receptor antagonist at a concentration that is greater than the concentration of interleukin-1 receptor antagonist in the white blood cell fraction or the white blood cell concentrate, wherein the concentration of interleukin-1 receptor antagonist in the solution is at least 10,000 pg/ml.
7. The solution according to claim 6 , wherein the white blood cells are activated by the polyacrylamide beads to release at least a portion of the interleukin-1 receptor antagonist.
8. The solution according to claim 6 , wherein the white blood cell fraction or the white blood cell concentrate has a white blood cell concentration of 28.5±4.8 K/μL.
9. A solution enriched in interleukin-1 receptor antagonist generated from a volume of whole blood, the solution comprising:
white blood cells;
polyacrylamide beads; and
interleukin-1 receptor antagonist at a concentration of at least 20,000 pg/ml; wherein the white blood cells are activated by the polyacrylamide beads to release at least a portion of the interleukin-1 receptor antagonist.
10. The solution according to claim 9 , wherein the white blood cells comprise from about 80% to about 90% of the white blood cells present in the volume of whole blood.
11. The solution according to claim 9 , wherein the concentration of interleukin-1 receptor antagonist in the solution is greater than the concentration of interleukin-1 receptor antagonist in the volume of the whole blood.
12. The solution according to claim 9 , wherein the concentration of interleukin-1 receptor antagonist in the solution is at least twice the concentration of interleukin-1 receptor antagonist in the volume of the whole blood.